212 related articles for article (PubMed ID: 36056809)
1. Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review.
LeFevre JD; Cyriac SL; Tokmic A; Pitlick JM
Am J Health Syst Pharm; 2022 Nov; 79(23):2099-2117. PubMed ID: 36056809
[TBL] [Abstract][Full Text] [Related]
2. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes.
Mignogna C; Maddaloni E; D'Onofrio L; Buzzetti R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1209-1219. PubMed ID: 34936848
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
Ashraf MT; Ahmed Rizvi SH; Kashif MAB; Shakeel Khan MK; Ahmed SH; Asghar MS
Diabetes Obes Metab; 2023 Nov; 25(11):3377-3389. PubMed ID: 37580969
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis.
Liu Y; Li W; Chen Y; Wang X
Endocrine; 2024 Feb; 83(2):322-329. PubMed ID: 37658243
[TBL] [Abstract][Full Text] [Related]
5. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
6. Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis.
Kamrul-Hasan ABM; Mondal S; Nagendra L; Yadav A; Aalpona FTZ; Dutta D
Endocr Pract; 2024 May; 30(5):431-440. PubMed ID: 38519028
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance.
Gaglia J; Kissler S
Biochemistry; 2019 Oct; 58(40):4107-4111. PubMed ID: 31523950
[TBL] [Abstract][Full Text] [Related]
9. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
[TBL] [Abstract][Full Text] [Related]
10. Immune therapy and β-cell death in type 1 diabetes.
Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD3 clinical trials in type 1 diabetes mellitus.
Daifotis AG; Koenig S; Chatenoud L; Herold KC
Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
[TBL] [Abstract][Full Text] [Related]
12. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
[TBL] [Abstract][Full Text] [Related]
13. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Aronson R; Gottlieb PA; Christiansen JS; Donner TW; Bosi E; Bode BW; Pozzilli P;
Diabetes Care; 2014 Oct; 37(10):2746-54. PubMed ID: 25011949
[TBL] [Abstract][Full Text] [Related]
14. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
15. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.
Demeester S; Keymeulen B; Kaufman L; Van Dalem A; Balti EV; Van de Velde U; Goubert P; Verhaeghen K; Davidson HW; Wenzlau JM; Weets I; Pipeleers DG; Gorus FK
Diabetes Care; 2015 Apr; 38(4):644-51. PubMed ID: 25583753
[TBL] [Abstract][Full Text] [Related]
16. Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.
Mamchak AA; Manenkova Y; Leconet W; Zheng Y; Chan JR; Stokes CL; Shoda LK; von Herrath M; Bresson D
Diabetes; 2012 Jun; 61(6):1490-9. PubMed ID: 22362174
[TBL] [Abstract][Full Text] [Related]
17. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
[TBL] [Abstract][Full Text] [Related]
18. Teplizumab therapy for type 1 diabetes.
Masharani UB; Becker J
Expert Opin Biol Ther; 2010 Mar; 10(3):459-65. PubMed ID: 20095914
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Herold KC; Hagopian W; Auger JA; Poumian-Ruiz E; Taylor L; Donaldson D; Gitelman SE; Harlan DM; Xu D; Zivin RA; Bluestone JA
N Engl J Med; 2002 May; 346(22):1692-8. PubMed ID: 12037148
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD3 mAbs for treatment of type 1 diabetes.
Kaufman A; Herold KC
Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
